Table 1.
Patient demographics and clinicopathological characteristics (n = 22).
| Characteristics | No. of patients |
|---|---|
| Sex | |
| Male | 15 (68.2%) |
| Female | 7 (31.8%) |
| Age, years | |
| Median (range) | 51 (7-79) |
| ECOG performance status | |
| 0 | 4 (18.2%) |
| 1 | 18 (81.8%) |
| Size of primary disease, cm | |
| Median (range) | 9.2 (3.0-17.0) |
| Location of primary lesions | |
| Head | 9 (40.9%) |
| Body/tail | 13 (59.1%) |
| Histology | |
| PACC | 19 (86.4%) |
| Mixed PACC | 3 (13.6%) |
| Common symptom | |
| Abdominal pain | 11 (50.0%) |
| Weight loss | 5 (28.6%) |
| Abdominal mass | 5 (28.6%) |
| Subcutaneous fat necrosis | 3 (13.6%) |
| Metastases at initial diagnosis | |
| Yes | 5 (22.7%) |
| No | 17 (77.3%) |
| Main metastatic site | |
| Liver | 10 (45.5%) |
| Distant lymph node | 6 (27.3%) |
| Peritoneum | 5 (22.7%) |
| Serum CA-199 | |
| Elevated | 7 (31.8%) |
| Normal | 15 (68.2%) |
| Serum AFP | |
| Elevated | 3 (13.6%) |
| Normal | 14 (63.6%) |
| Not available | 5 (22.7%) |
| Tumor family history | 4 (18.2%) |
| Non-metastases cases | n = 17 |
| Radical surgery | 17 (100%) |
| Adjuvant chemotherapy | 8 (47.1%) |
| Regional lymph node metastasis | 3 (17.6%) |
| High Ki-67 index (⩾30%) | 4 (23.5%) |
| Lymph-vascular invasion | 6 (35.3%) |
| Treatment for metastases cases | n = 14 |
| First palliative chemotherapy | 8 (57.1%) |
| Second palliative chemotherapy | 4 (28.6%) |
Abbreviations: AFP, alpha-fetoprotein; CA-199, carbohydrate antigen 199; ECOG, Eastern Cooperative Oncology Group; PACC, pancreatic acinar cell carcinoma.